Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Genfit stock falls over 5% and breaks its support at €11.56

The Lille-based biopharma company is experiencing a sharp setback at the start of the week, despite the stock having posted several positive catalysts in recent weeks. The decline occurs against a backdrop of a broadly bullish European market, making the correction all the more visible.


Genfit stock falls over 5% and breaks its support at €11.56

A marked decline that pushes the stock below its short and medium-term moving averages

Genfit falls 5.36% to €10.94 in trading, marking one of the sharpest declines on the SBF 120, in an index that is nonetheless up 0.76%. The move erases the last closing price at €11.56, which was precisely the support threshold identified for the stock. The price now stands clearly below the 20-day moving averages (€13.36, representing a -18.1% gap) and the 50-day moving average (€13.51, a -19% gap), two benchmarks that act as a technical ceiling weighing on any rebound attempt.

Only the 200-day MA at €9.29 remains below the current price, confirming that the long-term trend remains bullish despite recent turbulence. The RSI at 36 is approaching oversold territory without having reached it, reflecting ongoing selling exhaustion without an immediate reversal signal. The seven-day performance is now down nearly 16%, and 22.4% over one month, a correction that contrasts with the gain of over 200% recorded over one year.

Fundamentals in development, short positions gaining traction

The correction comes on the heels of a dense period of news for the group. Genfit's entry into the CAC Mid 60 and SBF 120 indices, effective after the close on Friday, September 18, 2026, had constituted a major institutional recognition. Earlier, the company had announced its intention to test nangibotide in acute decompensation of cirrhosis, a new indication that enriches its pipeline following the acquisition of this candidate during the summer of 2026. On the operational front, during the publication of Q1 2026 results on May 21, 2026, the momentum of royalties linked to Iqirvo had been presented as a favorable driver for financial margins. In this context, the rapid increase in short positions warrants attention: according to recorded disclosures, two funds cumulate 1.04% of capital sold short, up 1.04 percentage points over thirty days.

This level remains modest in absolute terms, but the recent acceleration indicates that certain institutional investors are positioning themselves against the stock's rise, or seeking to hedge an existing exposure. This point merits monitoring over time without drawing hasty conclusions about the price direction. The resistance level at €14.52 now represents the first hurdle to overcome for the long-term bullish trend to regain credibility in the short term.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36,4 millions d'euros
  • Quarterly revenue: 36,4 millions d'euros
  • Revenue growth: -7,1 %
Guidance from the release
  • « conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
  • Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
  • Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
  • Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
  • Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
  • Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
  • Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours